Erin Comerford

Patient-Reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-Body Injector vs Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma

Gurdeep Parmar, Marcelo Capra, Vania Hungria, Fernanda Salles Seguro et autres

au, br, kr, gr, cz, pt, jp, us, fr, gb (code pays fourni par la source)

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vania Hungria et autres

au, br, kr, gr, cz, pt, jp, fr, us, gb (code pays fourni par la source)

Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone

Robert Orlowski, Meletios Α. Dimopoulos, Xavier Leleu, Meral Beksaç et autres

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

Gurdeep Parmar, Vânia Hungria, Meletios Α. Dimopoulos, Sosana Delimpasi et autres

Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)

María-Victoria Mateos, Ivan Špıčka, Andrew Spencer, Albert Oriol et autres

The burden of metastatic breast cancer on caregiver productivity and quality of life: A survey study in the United States, United Kingdom, and Germany

Erin Comerford, Sukyung Chung, Marlon Graf, Natalie Land et autres

us (code pays fourni par la source)

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Meletios Α. Dimopoulos, Thierry Façon, Meral Beksaç, Luděk Pour et autres

gr, fr, tr, cz, cn, pl, de, jp, au, it, us (code pays fourni par la source)

HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators

Erin Comerford, Lindsey Norcross, Medha Sasané, Ying Zheng et autres

us (code pays fourni par la source)

Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)

Christina Slota, Lindsey Norcross, Erin Comerford, Medha Sasané et autres

us (code pays fourni par la source)

Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford et autres

us, fr (code pays fourni par la source)

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

Shirley Mertz, Christine Benjamin, Charis Girvalaki, Antonella Cardone et autres

us, pt (code pays fourni par la source)

HSR22-156: Patient Perspectives on Progression-Free Survival and Quality of Life in Metastatic Breast Cancer

Shirley Mertz, Christine Benjamin, Charis Girvalaki, Antonella Cardone et autres

us, be, pt (code pays fourni par la source)